SHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the Firm
Atlanta, Georgia--(Newsfile Corp. - April 16, 2021) - Holzer & Holzer, LLC reminds investors who suffered financial losses on purchases of Immunovant, Inc. ("Immunovant" or the "Company") (NASDAQ: IMVT) securities made between October 2, 2019 and February 1, 2021, inclusive, of an upcoming lead plaintiff deadline in the class action previously filed against the Company by the firm.
The complaint alleges Immunovant made false and/or misleading statements relating to, among other things, the merger of HSAC and Legacy Immunovant. The lawsuit seeks to recover money on behalf of investors who suffered losses resulting from those alleged false statements.
If you purchased shares of Immunovant between October 2, 2019 and February 1, 2021 and suffered significant losses on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or by toll-free telephone at (888) 508-6832 to discuss your legal rights or you may visit the firm's website at www.holzerlaw.com to learn more. If you wish to serve as lead plaintiff, you must move the Court no later than April 19, 2021.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80696
